<p>加利福尼亞州福斯特城，2025 年 12 月 9 日（GLOBE NEWSWIRE）——Terns Pharmaceuticals, Inc.（“Terns” 或 “公司”）（納斯達克：TERN），一家臨牀階段的腫瘤學公司，今天宣佈其增大規模的承銷公開發行價格為每股 40.00 美元的 16,250,000 股普通股，未扣除承銷折扣和佣金。此次發行的總收益預計為 6.5 億美元，未扣除承銷折扣和佣金及 Terns 需支付的其他發行費用，且不包括承銷商購買額外股份的選擇權。Terns 已授予承銷商一個 30 天的選擇權，以每股公開發行價格購買最多 2,437,500 股普通股，扣除承銷折扣和佣金。此次發行預計將於 2025 年 12 月 11 日完成，需滿足慣常的交割條件。所有證券均由 Terns 提供。</p>
<p>Jefferies、TD Cowen 和 Leerink Partners 擔任此次發行的主要賬簿管理人。Mizuho、Citizens Capital Markets 和 Oppenheimer &amp; Co.也擔任此次發行的共同管理人。</p>
<p>Terns 計劃將此次發行的淨收益用於資助研究、臨牀試驗、關鍵產品候選者的開發和生產，包括 TERN-701，準備 TERN-701 潛在未來商業發佈的初步活動，以及用於營運資金和一般企業用途。</p>
<p>關於此次公開發行的證券，已於 2025 年 12 月 9 日向證券交易委員會（“SEC”）提交了 S-3 表格的註冊聲明（文件編號 333-292016），並於該日期自動生效。此次發行僅通過補充招股説明書和構成註冊聲明一部分的招股説明書進行。與此次發行相關的初步補充招股説明書和招股説明書已提交給 SEC，並可在 SEC 網站 www.sec.gov 上獲取。與此次發行相關的最終補充招股説明書將提交給 SEC。初步補充招股説明書、最終補充招股説明書及與此次發行相關的招股説明書的副本在可用時可從 Jefferies LLC 索取，注意：股權承銷招股説明書部門，地址：520 Madison Avenue, New York, NY 10022，電話：877-821-7388，或通過電子郵件聯繫 prospectus_department@jefferies.com，TD Securities (USA) LLC，c/o Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，或通過電子郵件聯繫 TDManualrequest@broadridge.com，或 Leerink Partners LLC，注意：承銷部門，地址：53 State Street, 40th Floor, Boston, MA 02109，電話：1-800-808-7525 ex. 6105，或通過電子郵件聯繫 syndicate@leerink.com。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他管轄區內進行這些證券的出售，若在該州或其他管轄區內的證券法規定之前進行註冊或資格審查，則該出售將是非法的。</p>
<p><strong>關於 Terns Pharmaceuticals</strong></p>
<p>Terns Pharmaceuticals 是一家臨牀階段的腫瘤學公司，重新構想已知生物學，以提供高影響力的藥物。我們的主導項目 TERN-701 是一種高度選擇性的別構 BCR-ABL 抑制劑，具有潛在的最佳疾病特徵，可能在慢性髓性白血病（CML）現有治療的療效、安全性和便利性方面顯著改善。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本新聞稿包含關於 Terns Pharmaceuticals, Inc.（“公司”、“我們” 或 “我們的”）的前瞻性聲明，符合聯邦證券法的定義，包括擬議公開發行的預期關閉日期以及公司對擬議公開發行收益的預期使用，以及 TERN-701 的潛在臨牀特徵和相對優勢。除歷史事實聲明外，本新聞稿中包含的所有聲明均為前瞻性聲明。在某些情況下，您可以通過諸如 “目標”、“預期”、“假設”、“相信”、“考慮”、“繼續”、“可能”、“設計”、“由於”、“估計”、“期待”、“目標”、“打算”、“可能”、“目標”、“計劃”、“定位”、“潛在”、“預測”、“尋求”、“應該”、“目標”、“將”、“會” 等術語或其他類似表達來識別前瞻性聲明，這些術語是對未來事件和未來趨勢的預測或指示，或這些術語的否定形式或其他可比術語。公司在很大程度上基於其當前的預期、估計、預測和關於未來事件及財務趨勢的預測來制定這些前瞻性聲明，這些事件和趨勢可能會影響其財務狀況、經營結果、商業戰略和財務需求。鑑於這些前瞻性聲明中存在的重大不確定性，您不應將前瞻性聲明視為未來事件的預測。這些聲明受到風險和不確定性的影響，這可能導致實際結果和公司計劃的實施發生重大變化，包括與公司當前和未來的研究與開發活動、臨牀前研究和臨牀試驗的啓動、成本、時間、進展、結果和效用相關的風險。這些風險並不詳盡。有關可能影響公司和發行的風險因素的詳細討論，請參閲公司在 SEC 報告中識別的風險因素，包括但不限於截至 2024 年 12 月 31 日的年度報告（Form 10-K）、後續的季度報告（Form 10-Q）以及其初步招股説明書補充。除法律要求外，公司沒有義務因任何原因公開更新任何前瞻性聲明。</p>
<p><strong>Terns 聯繫方式</strong></p>
<p><strong>投資者</strong></p>
<p>Justin Ng</p>
<p>investors@ternspharma.com</p>
<p><strong>媒體</strong></p>
<p>Jenna Urban</p>
<p>CG Life</p>
<p>media@ternspharma.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOaU0zTXpFMU1EVTFJekl5TURReE5qTT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOaU0zTXpFMU1EVTFJekl5TURReE5qTT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png"/></p>

TERN

<p>Terns Pharmaceuticals 宣佈其增資的 6.5 億美元公開發行定價為每股 40 美元，共計 16,250,000 股。此次發行預計將於 2025 年 12 月 11 日完成，Jefferies、TD Cowen 和 Leerink Partners 擔任主承銷商。募集資金將用於研究、臨牀試驗以及 TERN-701 的開發等其他用途。公司已向美國證券交易委員會（SEC）提交了一個貨架註冊聲明，發行將通過招股説明書補充文件進行</p>

<p>FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns.</p>
<div class="lb-trans"><p>加利福尼亞州福斯特城，2025 年 12 月 9 日（GLOBE NEWSWIRE）——Terns Pharmaceuticals, Inc.（“Terns” 或 “公司”）（納斯達克：TERN），一家臨牀階段的腫瘤學公司，今天宣佈其增大規模的承銷公開發行價格為每股 40.00 美元的 16,250,000 股普通股，未扣除承銷折扣和佣金。此次發行的總收益預計為 6.5 億美元，未扣除承銷折扣和佣金及 Terns 需支付的其他發行費用，且不包括承銷商購買額外股份的選擇權。Terns 已授予承銷商一個 30 天的選擇權，以每股公開發行價格購買最多 2,437,500 股普通股，扣除承銷折扣和佣金。此次發行預計將於 2025 年 12 月 11 日完成，需滿足慣常的交割條件。所有證券均由 Terns 提供。</p>
</div><p>Jefferies, TD Cowen and Leerink Partners are acting as lead book-running managers for the proposed offering. Mizuho, Citizens Capital Markets and Oppenheimer &amp; Co. are also acting as co-managers for the proposed offering.</p>
<div class="lb-trans"><p>Jefferies、TD Cowen 和 Leerink Partners 擔任此次發行的主要賬簿管理人。Mizuho、Citizens Capital Markets 和 Oppenheimer &amp; Co.也擔任此次發行的共同管理人。</p>
</div><p>Terns intends to use the net proceeds from the proposed offering to fund research, clinical trials, development and manufacturing of key product candidates, including TERN-701, initial activities in preparation for the potential future commercial launch of TERN-701 and for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Terns 計劃將此次發行的淨收益用於資助研究、臨牀試驗、關鍵產品候選者的開發和生產，包括 TERN-701，準備 TERN-701 潛在未來商業發佈的初步活動，以及用於營運資金和一般企業用途。</p>
</div><p>A shelf registration statement on Form S-3 (File No. 333-292016) relating to the securities offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on December 9, 2025 and automatically became effective on such date. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the preliminary prospectus supplement, final prospectus supplement, and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com, TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com, or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ex. 6105, or by email at syndicate@leerink.com.</p>
<div class="lb-trans"><p>關於此次公開發行的證券，已於 2025 年 12 月 9 日向證券交易委員會（“SEC”）提交了 S-3 表格的註冊聲明（文件編號 333-292016），並於該日期自動生效。此次發行僅通過補充招股説明書和構成註冊聲明一部分的招股説明書進行。與此次發行相關的初步補充招股説明書和招股説明書已提交給 SEC，並可在 SEC 網站 www.sec.gov 上獲取。與此次發行相關的最終補充招股説明書將提交給 SEC。初步補充招股説明書、最終補充招股説明書及與此次發行相關的招股説明書的副本在可用時可從 Jefferies LLC 索取，注意：股權承銷招股説明書部門，地址：520 Madison Avenue, New York, NY 10022，電話：877-821-7388，或通過電子郵件聯繫 prospectus_department@jefferies.com，TD Securities (USA) LLC，c/o Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，或通過電子郵件聯繫 TDManualrequest@broadridge.com，或 Leerink Partners LLC，注意：承銷部門，地址：53 State Street, 40th Floor, Boston, MA 02109，電話：1-800-808-7525 ex. 6105，或通過電子郵件聯繫 syndicate@leerink.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他管轄區內進行這些證券的出售，若在該州或其他管轄區內的證券法規定之前進行註冊或資格審查，則該出售將是非法的。</p>
</div><p><strong>About Terns Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>關於 Terns Pharmaceuticals</strong></p>
</div><p>Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for CML.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals 是一家臨牀階段的腫瘤學公司，重新構想已知生物學，以提供高影響力的藥物。我們的主導項目 TERN-701 是一種高度選擇性的別構 BCR-ABL 抑制劑，具有潛在的最佳疾病特徵，可能在慢性髓性白血病（CML）現有治療的療效、安全性和便利性方面顯著改善。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including the anticipated closing date of the proposed public offering and the Company’s anticipated use of proceeds of the proposed public offering and the potential clinical profile and relative benefits of TERN-701. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and its preliminary prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</p>
<div class="lb-trans"><p>本新聞稿包含關於 Terns Pharmaceuticals, Inc.（“公司”、“我們” 或 “我們的”）的前瞻性聲明，符合聯邦證券法的定義，包括擬議公開發行的預期關閉日期以及公司對擬議公開發行收益的預期使用，以及 TERN-701 的潛在臨牀特徵和相對優勢。除歷史事實聲明外，本新聞稿中包含的所有聲明均為前瞻性聲明。在某些情況下，您可以通過諸如 “目標”、“預期”、“假設”、“相信”、“考慮”、“繼續”、“可能”、“設計”、“由於”、“估計”、“期待”、“目標”、“打算”、“可能”、“目標”、“計劃”、“定位”、“潛在”、“預測”、“尋求”、“應該”、“目標”、“將”、“會” 等術語或其他類似表達來識別前瞻性聲明，這些術語是對未來事件和未來趨勢的預測或指示，或這些術語的否定形式或其他可比術語。公司在很大程度上基於其當前的預期、估計、預測和關於未來事件及財務趨勢的預測來制定這些前瞻性聲明，這些事件和趨勢可能會影響其財務狀況、經營結果、商業戰略和財務需求。鑑於這些前瞻性聲明中存在的重大不確定性，您不應將前瞻性聲明視為未來事件的預測。這些聲明受到風險和不確定性的影響，這可能導致實際結果和公司計劃的實施發生重大變化，包括與公司當前和未來的研究與開發活動、臨牀前研究和臨牀試驗的啓動、成本、時間、進展、結果和效用相關的風險。這些風險並不詳盡。有關可能影響公司和發行的風險因素的詳細討論，請參閲公司在 SEC 報告中識別的風險因素，包括但不限於截至 2024 年 12 月 31 日的年度報告（Form 10-K）、後續的季度報告（Form 10-Q）以及其初步招股説明書補充。除法律要求外，公司沒有義務因任何原因公開更新任何前瞻性聲明。</p>
</div><p><strong>Contacts for Terns</strong></p>
<div class="lb-trans"><p><strong>Terns 聯繫方式</strong></p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投資者</strong></p>
</div><p>Justin Ng</p>
<div class="lb-trans"><p>Justin Ng</p>
</div><p>investors@ternspharma.com</p>
<div class="lb-trans"><p>investors@ternspharma.com</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒體</strong></p>
</div><p>Jenna Urban</p>
<div class="lb-trans"><p>Jenna Urban</p>
</div><p>CG Life</p>
<div class="lb-trans"><p>CG Life</p>
</div><p>media@ternspharma.com</p>
<div class="lb-trans"><p>media@ternspharma.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzNOaU0zTXpFMU1EVTFJekl5TURReE5qTT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg3NiM3MzE1MDU1IzIyMDQxNjM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZGE4MTYxNjEtZjViNy00MDI1LWE2YmYtYzI3NTllZTcwMmJjLTEyMTU3MTYtMjAyNS0xMi0xMC1lbg==/tiny/Terns-Pharmaceuticals-Inc-.png"/></p>

Terns 宣佈其擴大至 6.5 億美元的公開發行定價 | TERN 股票新聞